Blood, thrombosis & hemostasis

2017

Bouckaert C, Zhu S, Govers-Riemslag JWP, Depoorter M, Diamond SL, Pochet L. Discovery and assessment of water soluble coumarins as inhibitors of the coagulation contact pathway. Thromb Res. 2017 Jul 19;157:126-133.

Vornicu O, Larock AS, Dincq AS, Douxfils J, Dogné JM, Mullier F, Lessire S. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opin Biol Ther. 2017 Jul 20:1-22.

Sennesael AL, Exner T, Chatelain B, Lessire S, Larock AS, Vancraeynest C, Pochet L, Dogné JM, Spinewine A, Mullier F, Douxfils J. An optimized dRVVT-based  assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thromb Res. 2017 Jun 28;157:29-37.

Ronez E, Geara C, Coito S, Jacqmin H, Cornet E, Troussard X, Chatelain B, Mullier F. Usefulness of thresholds for smear review of neutropenic samples analyzed with a Sysmex XN-10 analyzer. Scand J Clin Lab Invest. 2017 Jun 13:1-4.

Wannez A, Devalet B, Bouvy C, Laloy J, Bihin B, Chatelain B, Chatelain C, Dogné JM, Mullier F. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thromb Res. 2017 Jun 9;156:142-148.

Sabor L, Raphaël M, Dogné JM, Mullier F, Douxfils J. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thromb Res. 2017 May 25;156:36-38.

Tamigniau A, Bailly N, Chatelain B, Mullier F. From XE-2100 to XN-9000, from SIS Standard to GFHC recommendations for slide review: potential impact on review rate and turnaround time. Ann Biol Clin (Paris). 2017 Jun 1;75(3):285-292.

Dubois V, Dincq AS, Douxfils J, Ickx B, Samama CM, Dogné JM, Gourdin M, Chatelain B, Mullier F, Lessire S. Perioperative management of patients on direct oral anticoagulants. Thromb J. 2017 May 15;15:14.

Minet V, Dogné JM, Mullier F. Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review. Molecules. 2017 Apr 11;22(4).

Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J, Deneys V, Bihin B, Chatelain B, Dogné JM, Chatelain C, Mullier F. Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. Blood Transfus. 2017 Mar 9:1-10.

Horlait G, Minet V, Mullier F, Michaux I. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report. Blood Coagul Fibrinolysis. 2017 Mar;28(2):193-197.

Douxfils J, Gosselin RC. Laboratory Assessment of Direct Oral Anticoagulants. Semin Thromb Hemost. 2017 Apr;43(3):277-290.

Gheldof D, Haguet H, Dogné J-M, Bouvy C, Graux C, George F, Sonet A, Chatelain C, Chatelain B, Mullier F. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. J Thromb Thrombolysis. 2017 Feb;43(2):224-232.

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis. Expert Opin Drug Saf. 2017 Jan;16(1):5-12.

2016

Magnette A, Chatelain M, Chatelain B, Ten Cate H, Mullier F. Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thromb J. 2016 Dec 12;14:49.

Despas N, Larock AS, Jacqmin H, Douxfils J, Chatelain B, Chatelain M, Mullier F. Heparin monitoring: clinical outcome and practical approach. Ann Biol Clin (Paris). 2016 Dec 1;74(6):637-652.

Morel-Kopp MC, Mullier F, Gkalea V, Bakchoul T, Minet V, Elalamy I, Ward CM; subcommittee on platelet immunology. Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH. J Thromb Haemost. 2016 Sep 26.

Lessire S, Douxfils J, Pochet L, Dincq AS, Larock AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. Clin Appl Thromb Hemost. 2016 Nov 3.

Lessire S, Douxfils J, Dincq AS, Mullier F. Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests. Reg Anesth Pain Med. 2016 Nov/Dec;41(6):787-788.

Petrey AC, Obery DR, Kessler SP, Flamion B, de la Motte CA. Hyaluronan Depolymerization by Megakaryocyte Hyaluronidase-2 Is Required for Thrombopoiesis. Am J Pathol. 2016 Sep;186(9):2390-403.

Cornet E, Mullier F, Despas N, Jacqmin H, Geara C, Boubaya M, Chatelain B, Troussard X. Evaluation and optimization of the extended information process unit (E-IPU) validation module integrating the sysmex flag systems and the recommendations of the French-speaking cellular hematology group (GFHC). Scand J Clin Lab Invest. 2016 Oct;76(6):465-71.

Douxfils J, Haguet H, Dogné JM. Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-Reply. JAMA Oncol. 2016 Jun 1;2(6):829

Cai H, Mullier F, Frotscher B, Briquel ME, Toussaint M, Massin F, Lecompte T, Latger-Cannard V. Usefulness of Flow Cytometric Mepacrine Uptake/Release Combined with CD63 Assay in Diagnosis of Patients with Suspected Platelet Dense Granule Disorder. Semin Thromb Hemost. 2016 Apr;42(3):282-91.

Bouckaert C, Serra S, Rondelet G, Dolušić E, Wouters J, Dogné JM, Frédérick R, Pochet L. Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitors. Eur J Med Chem. 2016 Mar 3;110:181-94.

Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Feb 4.

Douxfils J, Chatelain B, Chatelain C, Dogné JM, Mullier F. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost. 2016 Jan 27;115(2):368-81.

2015

Gouin-Thibault I, Larock AS, Douxfils J, Mullier F. Which method of renal function evaluation is best appropriate in patients with direct oral anticoagulants? Ann Biol Clin (Paris). 2015 Dec 1;73(6):745-747.

Poncelet P, Robert S, Bailly N, Garnache-Ottou F, Bouriche T, Devalet B, Segatchian JH, Saas P, Mullier F. Tips and tricks for flow cytometry-based analysis and counting of microparticles. Transfus Apher Sci. 2015 Oct;53(2):110-26.

Lessire S, Douxfils J, Baudar J, Bailly N, Dincq AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thromb Res. 2015 Sep;136(3):693-6.

Minet, V., Alpan, L., Mullier, F., Toussaint, O., Lucas, S., Dogné, J.-M., Laloy, J. The euglobulin clot lysis time to assess the impact of nanoparticles on fibrinolysis (2015) Journal of Nanoparticle Research, 17 (7), art. no. 317, 9 p.

Sennesael AL, Dogné JM, Spinewine A. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment. (2015) JAMA Internal Medicine, 175 (10), pp. 1608-1609.

EVpedia: A community web portal for extracellular vesicles research (2015) Bioinformatics, 31 (6), pp. 933-939.

Douxfils J, Mullier F, Dogné JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015 Aug;14(8):1283-9.

Douxfils J, Mani H, Minet V, Devalet B, Chatelain B, Dogné JM, Mullier F. Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. Biomed Res Int. 2015;2015:345138.

Minet V, Bailly N, Dogné JM, Mullier F. Platelet microparticle generation assay for heparin-induced thrombocytopenia diagnosis: How should we express the results? Thromb Res. 2015 Jul;136(1):175-7.

Mani H, Douxfils J, Ansell J. Target-Specific Oral Anticoagulants-New Approaches in the Field of Oral Anticoagulation. Biomed Res Int. 2015;2015:549803.

Onclinx C, Dogne S, Jadin L, Andris F, Grandfils C, Jouret F, Mullier F, Flamion B. Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy. Haematologica 2015 Aug;100(8):1023-30.

Mullier F, Douxfils J, Tamigniau A, Dogné JM, Horellou MH, Flaujac C, Chatelain B, Goffinet C, Samama MM, Gouin-Thibault I. Non-VKA oral anticoagulants: an update for the clinical biologists Ann Biol Clin (Paris). 2015 May-Jun;73(3):333-44.

Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015 Sep;95(3):190-8.

Douxfils J, Chatelain B, Hjemdahl P, Devalet B, Sennesael AL, Wallemacq P, Rönquist-Nii Y, Pohanka A, Dogné JM, Mullier F. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res. 2015 May;135(5):852-60.

Douxfils J, Chatelain B, Dogné JM, Mullier F. Real-world variability in dabigatran levels in patients with. atrial fibrillation: comment J Thromb Haemost. 2015 Jun;13(6):1166-8.

Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Rönquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogné JM, Mullier F. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2015 Apr;113(4):862-9.

2014

Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné JM, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J. 2014 Nov 4;12:24.

Larock AS, Mullier F, Sennesael AL, Douxfils J, Devalet B, Chatelain C, Dogné JM, Spinewine A. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother. 2014 Oct;48(10):1258-68.

Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review. J Extracell Vesicles. 2014 Mar 24;3.

Bouvy C, Gheldof D, Chatelain C, Mullier F, Dogne JM. Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. Journal of extracellular vesicles 2014, 3.

Dincq AS, Lessire S, Douxfils J, Dogne JM, Gourdin M, Mullier F Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. BioMed research international 2014, 2014:385014.

Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyere O, Dogne JM Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association 2014, 3:e000515.

Gheldof D, Chatelain C, Dogne JM, Mullier F Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thrombosis research 2014, 134:213-214.

Gheldof D, Mullier F, Bailly N, Devalet B, Dogne JM, Chatelain B, Chatelain C Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state. Thrombosis research 2014, 133:433-439.

Minet V, Baudar J, Bailly N, Douxfils J, Laloy J, Lessire S, Gourdin M, Devalet B, Chatelain B, Dogné JM, Mullier F. Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. Thrombosis research 2014, 133:1074-1078.

Mullier F, Minet V, Bailly N, Devalet B, Douxfils J, Chatelain C, Elalamy I, Dogne JM, Chatelain B Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis. Thrombosis research 2014, 133:1068-1073.

Mullier F, Vanpee D, Jamart J, Dubuc E, Bailly N, Douxfils J, Chatelain C, Dogne JM, Chatelain B Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2014, 25:309-315.

Lessire, S., Dincq, A.-S., Douxfils, J., Devalet, B., Nicolas, J.-B., Spinewine, A., Larock, A.-S., Dogné, J.-M., Gourdin, M., Mullier, F. Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants (2014) BioMed Research International, 2014, art. no. 616405.

Tamigniau, A., Douxfils, J., Nicolas, J.-B., Devalet, B., Larock, A.-S., Spinewine, A., Dincq, A.-S., Lessire, S., Gourdin, M., Watelet, J.-B., Mathieux, V., Chatelain, C., Dogné, J.-M., Chatelain, B., Mullier, F. Why, when and how monitor new oral anticoagulants? [Pourquoi, quand et comment doser les nouveaux anticoagulants oraux?] (2014) Revue Medicale Suisse, 10 (416), pp. 326-333.

J Laloy, V Minet, L Alpan, F Mullier, S Beken, O Toussaint, S Lucas and J-M Dogné. Impact of Silver Nanoparticles on Haemolysis, Platelet Function and Coagulation. Nanobiomedicine, 2014, 1:4.

2013

Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, Mullier F Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thrombosis and haemostasis 2013, 110:723-731.

Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thrombosis and haemostasis 2013, 110:283-294.

Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, Hjemdahl P Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thrombosis and haemostasis 2013, 110:543-549.

Gheldof D, Mullier F, Chatelain B, Dogne JM, Chatelain C Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2013, 24:567-572.

Gheldof D, Hardij J, Cecchet F, Chatelain B, Dogne JM, Mullier F Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. Journal of extracellular vesicles 2013 Mar 18;2.

Hardij J, Cecchet F, Berquand A, Gheldof D, Chatelain C, Mullier F, Chatelain B, Dogne JM Characterisation of tissue factor-bearing extracellular vesicles with AFM: comparison of air-tapping-mode AFM and liquid Peak Force AFM Journal of extracellular vesicles 2013, Aug 27;2.

Minet V, Bailly N, Douxfils J, Osselaer JC, Laloy J, Chatelain C, Elalamy I, Chatelain B, Dogne JM, Mullier F Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: a retrospective study Thrombosis research 2013, 132:352-359.

Mullier F, Bailly N, Chatelain C, Chatelain B, Dogne JM Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions. Journal of thrombosis and haemostasis : JTH 2013, 11:693-696.

Pochet L, Servais AC, Farcas E, Bettonville V, Bouckaert C, Fillet M Determination of inhibitory potency of argatroban toward thrombin by electrophoretically mediated microanalysis Talanta 2013, 116:719-725.

2012

Mullier F, Rahier JF, Maignen F, Cornet Y, Graux C, Chatelain C, Chatelain B, Dogne JM A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine Acta haematologica 2012, 128:1-6.

Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature Thrombosis research 2012, 130:956-966.

Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thrombosis and haemostasis 2012, 107:985-997.

Laloy J, Robert S, Marbehant C, Mullier F, Mejia J, Piret JP, Lucas S, Chatelain B, Dogné JM, Toussaint O, Masereel B, Rolin S. Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. Nanotoxicology 2012, 6:213-232.

Mullier F, Bailly N, Cornet Y, Robert S, Osselaer JC, Chatelain C, Elalamy I, Dogne JM, Chatelain B Platelet microparticle generation assay: A valuable predictor of clinical outcome in heparin-induced thombocytopenia diagnosis. Immuno-analyse&biologie spécialisée 2012, 27:41.

Mullier F, Daliphard S, Garand R, Dekeyser M, Cornet Y, Luquet I, Talmant P, Richebourg S, Jamar M, Dogné JM, Chatelain C, Michaux L, Chatelain B. Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study Annals of hematology 2012, 91:203-213.

Mullier F, Daliphard S, Garand R, Dekeyser M, Cornet Y, Luquet I, Talmant P, Richebourg S, Jamar M, Dogne JM, Chatelain C, Michaux L, Chatelain B. Hypogranulated and vacuolized neutrophils and neutrophil erythrophagocytosis is a useful marker in myelodysplasia with del(20q): A multicentre stydy. Immuno-analyse&biologie spécialisée 2012, 27:42-43.

Mullier F, Laloy J, Robert S, Alpan L, Meija J, Piret J, Bailly N, Lucas S, Chatelain B, Toussaint O, B. Masereel, S. Rolin & JM Dogne. Assessment of different methods studying the impact of carbon nanomaterials on platelet function Immuno-analyse Biologie Spécialisée 2012, 27:41.

Mullier F, Vanpee D, Amart J, Dubuc E, Cornet Y, Chatelain C, Dogne JM, Chatelain B Comparison of five D-dimer reagents and application of an age adjusted cut-off for the diagnosis of venous thromboembolic disease in emergency departement Immuno-analyse&biologie spécialisée 2012, 27:42.

Mullier F, Varin E, Gheldof D, Hardij J, Robert S, Bailly N, Devel P, Doyen C, Chatelain C, Michiels C, Chatelain B, Dogne JM Thrombin generation, flow cytometry and electron microscopy is a useful combination to study tissue-factor bearing microparticles in thrombosis associated with breast cancer Immuno-analyse&biologie spécialisée 2012, 27:43.

Sternotte A, Douxfils J, Chatelain B, Chatelain C, Mullier F, Dogne JM, Spinewine A [Clinical studies, the interests and limits of using dabigatran in atrial fibrillation] Journal de pharmacie de Belgique 2012:8-17.

2011

Mullier F, Bailly N, Chatelain C, Dogné JM, Chatelain B. More on: calibration for the measurement of microparticles:Needs, interests, and limitations of calibrated polystyrene beads for flow cytometry-based quantification of biological microparticles.  Thromb Haemost. 2011 Aug;9(8):1679-81; author reply 1681-2.

Mullier F, Lainey E, Fenneteau O, Da Costa L, Schillinger F, Bailly N, Cornet Y, Chatelain C, Dogne JM, Chatelain B. Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study. Ann Hematol, 2011 Jul;90(7):759-68.